ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0223

A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study

Ricardo Sabido-Sauri1, Seyyid Bilal Acikgoz2, Ozun Bayindir Tsechelidis3, Ummugulsum Gazel1, Sylvia Sangwa4, Elliot Hepworth1 and Sibel Aydin5, 1University of Ottawa, Ottawa, ON, Canada, 2University of Ottawa, Rheumatology, Ottawa, ON, Canada, 3Ottawa University, Ottawa, ON, Canada, 4The Ottawa Hospital Research Institute, Ottawa, Canada, 5University of Ottawa - Ottawa, Ottawa, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Biologicals, Comorbidity, Patient reported outcomes, Psoriatic arthritis, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment options, a better understanding of Difficult-to-Treat (D2T) PsA is essential and timely.  In this analysis, we aimed to explore the D2T PsA patient phenotype, by comparing the clinical features, comorbidities, and ultrasonographic features of peripheral arthritis and enthesitis domains with non-DT2 PsA, to understand factors contributing to the D2T state.

Methods: Patients were recruited from the ORCHESTRA (Ottawa Rheumatology CompreHEnSive Treatment and Assessment) Clinic, where all patients with inflammatory arthritis who are about to initiate a new advanced therapy are assessed using a standardized protocol including disease features, medications, comorbidities, and clinical disease activity measures. A protocoled ultrasound (US) was performed including 44 joints for synovitis and 14 entheses for enthesitis. Synovitis was scored using the Global OMERACT-EULAR Synovitis Score (GLOESS). Elementary lesions of enthesitis included hypoechogenicity, thickening, and power Doppler signals (features of inflammation) and erosions, calcifications, and enthesophytes (features of damage), all being on a scale of 0-3 (none-mild-moderate-severe). Relevant features were summed to reach inflammation, damage, and total enthesitis scores per patient. For this analysis, D2T PsA definitions were extrapolated from the EULAR definition of D2T Rheumatoid Arthritis. (1) Patients who fulfilled the D2T PsA definition were compared with the patients who did not fulfill (non-D2T).

Results: Among 52 PsA patients, 16 (30.8%) fulfilled the definition of D2T PsA. Demographics were similar between the two groups, except the male sex being numerically higher in D2T PsA patients (n=10/16 (62.5%) vs n=13/36 (36.1%); p=0.077) and having longer disease duration (table 1). Disease activities were similar between groups, both clinically and on US, and CRP levels were even lower in D2T PsA patients (p=0.022). Gout and inflammatory bowel disease were statistically higher in D2T PsA patients than non-D2T group (table 1).

Conclusion: There were no clinical and ultrasonographic differences in peripheral arthritis and enthesitis domains between patients with D2T and non-D2T PsA. In our patient population, comorbidities, gout, and inflammatory bowel disease seem to be associated with D2T state, but not necessarily a higher disease burden.

Supporting image 1


Disclosures: R. Sabido-Sauri: None; S. Acikgoz: None; O. Bayindir Tsechelidis: Janssen, 5; U. Gazel: None; S. Sangwa: None; E. Hepworth: None; S. Aydin: AbbVie/Abbott, 1, 2, 5, 6, Clarius, 11, Eli Lilly, 5, 6, Janssen, 1, 5, 6, Novartis, 1, 2, 5, 6, Pfizer, 1, 2, 5, 6, UCB, 1, 5, 6.

To cite this abstract in AMA style:

Sabido-Sauri R, Acikgoz S, Bayindir Tsechelidis O, Gazel U, Sangwa S, Hepworth E, Aydin S. A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/a-comparative-study-of-difficult-to-treat-vs-non-difficult-to-treat-psoriatic-arthritis-for-disease-burden-and-comorbidities-an-ultrasound-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-comparative-study-of-difficult-to-treat-vs-non-difficult-to-treat-psoriatic-arthritis-for-disease-burden-and-comorbidities-an-ultrasound-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology